The molecular basis that the viral oncoproteins, including HPV16 E6 and E1B55k/E4 34k complex, dierentially target p53 but not its homolog p73 for degradation remains elusive. Using a series of p53/p73 chimeras, we demonstrated that despite binding to the dierent regions of p53, both HPV16 E6 and E1B55k/E4 34k required a very same p53 sequence, amino acid residues 92 to 112 [p53(aa.92 ± 112)], previously identi®ed as a necessity for Mdm2-mediated degradation, to target p53 for degradation. Removal of the p53(aa.92 ± 112) by either substitution or deletion resulted in a p53 protein that was no longer degradable by the viral proteins. More signi®-cantly, swapping the oncoprotein-binding motif and the p53(aa.92 ± 112) rendered p73 susceptible to oncoproteinmediated degradation. Collectively, our data supports a model in which the p53(aa.92 ± 112) functions as a determinant for p53 stability while the binding of the oncoproteins directs p53 into the speci®c pathway for proteolysis. Oncogene (2001) 20, 3519 ± 3527.
Introduction
p53 is a central component of the cellular defense system that protects against the development of cancer (Levine, 1997) . In line with this notion, p53 knockout mice develop tumors at a very young age (Armstrong et al., 1995; Donehower et al., 1992; Donehower, 1996) . In addition to mutation, a substantial proportion of tumors inactivate p53's function through alternative mechanisms (Levine, 1997) . The binding of Mdm2 to p53 results in an inhibition of p53 transcriptional activity and a rapid degradation of p53 protein (Haupt et al., 1997; Kubbutat et al., 1997) . p53 is also a common target of several oncoproteins derived from dierent viruses. Most signi®cant with respect to human carcinogenesis is the E6 oncoprotein of human papillomavirus (HPV) that has been etiologically associated with cervical cancer. HPV16 E6 inactivates p53 by promoting p53 degradation (Schener et al., 1990) . Similarly, the oncoprotein E1B55k of the adenovirus (Kao et al., 1990; Yew and Berk, 1992) binds to and, consequently, inactivates p53. Recent studies reported that adenoviral protein, E1B55k forms a complex with E4 34k, and the two act synergistically to target p53 for rapid degradation (Querudi et al., 1997; Roth et al., 1998; Steegenga et al., 1999) .
p73, a recently identi®ed member of the p53 family, exhibits a high degree of sequence homology to the p53 transactivation, DNA binding and oligomerization domains (Kaghad et al., 1997) . The structural similarity indeed renders p73 able to activate the transcription of p53-responsive promoters and to induce apoptosis (Jost et al., 1997) . p73, however, is resistant to Mdm2-targeted degradation (Balint et al., 1999; Dobbelstein et al., 1999; Zeng et al., 1999) and is also not targeted by the viral oncoproteins Marin et al., 1998; Prabhu et al., 1998; Roth et al., 1998; Steegenga et al., 1999) . This distinct response of p53 and p73 to the oncoproteins suggests the presence of a unique structural element in p53 that contributes to its susceptibility to the inactivation by the oncoproteins. In an attempt to understand the dierential responses of p53 and p73 to Mdm2-directed degradation, we recently generated a series of p53/p73 chimeras that allowed us to identify a unique sequence in p53 that is required for Mdm2-mediated degradation (Gu et al., 2000) . The same set of p53/p73 chimeras was used in this report to dissect the distinct susceptibility of p53 and p73 to the viral oncoproteins. Interestingly, we found that the viral oncoproteins require the very same unique sequence element of p53, the p53(aa.92 ± 112) that is necessary for Mdm2-mediated degradation, to target p53 for degradation. These ®ndings led us to propose a model where the p53(aa.92 ± 112) functions as an intrinsic structural element that determines its stability while binding of the oncoproteins directs p53 to the speci®c pathway for degradation. p53 binds to E6 is still not well de®ned. Since p73 does not bind to E6 (Marin et al., 1998) , we utilized the p53/ p73 chimeras that retained their wild type conformation and transcription function (Gu et al., 2000) to determine the E6 binding domain of p53. The p53/ p73 chimeras were generated in such a way that a region of p73 replaced the corresponding domain of p53 (Gu et al., 2000) . If a particular region of p53 were required for E6 binding, swapping this region would cause the p53 chimera to lose the ability of binding to E6 while the corresponding p73 chimera to gain the ability of binding to E6. To test this, cell lysates prepared from 293 cells expressing the Flag-p53/p73 chimeras were incubated with GST-E6. The bound proteins were resolved by SDS ± PAGE and analysed by immunobloting with an anti-Flag antibody. As expected, the GST-E6 eciently bound to wild type p53, with a recovery of about 20% (Figure 1a, lane 3) , while the control GST did not bind to any detectable p53 ( Figure 1a , lane 2). Consistent with the previous report (Marin et al., 1998) , p73 did not bind to GST-E6 ( Figure 1a , lane 6). To determine the E6-binding domain, the indicated p53/p73 chimeras (Figure 1b left) were analysed for their ability to bind to GST-E6. The result demonstrated a binding of E6 to the Cterminus of p53, as evidenced by that the p53 chimera that had its C-terminus swapped with that of p73 failed to bind to GST-E6 while the corresponding p73 chimera gained an ability of binding to E6 (Figure 1b  right, lanes 15, 16) . In keeping with the binding of p53's C-terminus to E6, switching the N-terminal transactivation domain (TAD) and the central DNA-binding domain (DBD) had no eect on the E6 binding ( Figure  1b right, lanes 9 ± 14). To further de®ne the E6-binding region, a series of p53/p73 chimeras with smaller region swapped at the C-terminus (Figure 1c left) were tested. As shown in Figure 1c , switching amino acid sequence from 291 to 318 or 319 to 364 or p53 had no eect on its ability to bind to E6 (Figure 1c right, lanes 7 ± 10). When the amino acid sequence from 364 to 393 of p53 was replaced by the corresponding region of p73, however, the p53 chimera lost its E6 binding activity while the corresponding p73 chimera gained such activity (Figure 1c right, lanes 11, 12) . Taken together, Figure 1 The amino acid 364 ± 393 of p53 and the p53DBD are responsible for binding to HPV16 E6. (a) Lysates from cells expressing Flag-p53 or p73 was incubated with puri®ed GST or GST-E6 fusion protein. The adsorbates were analysed by SDS ± PAGE followed by Western blot with an anti-Flag antibody, 5% of the whole cell lysates was loaded as input. (b) Constructs expressing the indicated chimeras (left, the gray portion represents p53 and white part originates from p73) were transfected into 293T cells and the cell lysates were subjected to binding assay with GST-E6. The adsorbates were analysed by SDS ± PAGE and Western blot (right). (c) Lysates prepared from cells expressing p53/p73 chimeras with more re®ned switching at the C-terminus (left) were tested for binding to E6. The adsorbates were analysed by SDS ± PAGE and Western blot (right). (d) The Flag-tagged vector expressing the indicated chimeras were in vitro translated in the reticulocyte lysate. The products were incubated with GST-E6. Proteosome inhibitor (ALLN, Sigma, 80 mM) was included to prevent degradation of the chimeras. The adsorbates were analysed as described above the results clearly demonstrated that p53 associates with E6 through its C-terminal amino acid sequence from 364 to 393.
An additional protein, E6-associated protein (E6-AP), is required for E6-mediated degradation (Schener et al., 1993) . The E6-AP, however, is a ubiquitous expressed cellular protein and does not interact with p53 in the absence of oncogenic E6 (Huibregtse et al., 1991; Schener et al., 1993) . It has been demonstrated that the E6/E6-AP complex functions as a E3 ligase to target p53 for degradation (Huibregtse et al., 1991; Schener et al., 1993) . Li and Cono (1996a) showed that in addition to the p53 C-terminus, E6 also interacted with the residues 66 ± 326 of p53, which was not evident in our GST-fusion protein-binding assay. The lack of the E6 binding to the p53(aa.66 ± 326) in our assay could be due to that the association of E6 with the p53(66-326) was mediated by E6-AP, which was in very low abundance in our assay system. To test this, we used reticulocyte lysate as a source of E6-AP (Li and Cono, 1996a; Schener et al., 1993) to perform the binding assays in the presence of proteosome inhibitor. Since binding of E6 to the p53 C-terminus (Figure 1b, c) could interfere with the detection of binding of E6 to other p53's domain, we used the chimera p53/p73bCTc lacking the C-terminal binding domain. As shown in Figure 1d , in the presence of E6-AP, an association between GST-E6 and the p53/p73bCTc was indeed detected (Figure 1d , lane 7), indicating a binding of the E6 to the region of p53 other than the C-terminus via the E6-AP. Under the same condition, p73b/p53DBD and p73b/p53(aa.92 ± 290) (lanes 11,12), but not wild type p73b, p73b/p53NT or p73b/p53(aa.92 ± 112) (lanes 8 ± 10), exhibited a binding to GST-E6, indicating the p53DBD (residues 113 ± 290) as an additional domain that interacts with E6 through E6-AP. Taken together, our data con®rmed and extended the previous results (Li and Cono, 1996a; Huibregtse et al., 1991; Marston et al., 1995; Schener et al., 1993) by de®ning the two domains of p53 that HPV16 E6 interacts with, the last thirty residues at the p53 C-terminus that E6 directly binds to and the p53(aa.113 ± 290) that E6 associates with only in the presence of E6-AP.
Contribution of p53 domains to E6-mediated degradation
Having shown two separate regions of p53 that bind to oncogenic E6 protein, we asked how p53 domain contributed to its sensitivity to E6-targeted degradation. To this end, we adapted an in vitro degradation assay system (Schener et al., 1990 ) with a minor modi®cation to assess the susceptibility of the p53/p73 chimeras to HPV16 E6-mediated degradation. As shown in Figure  2a , incubation of puri®ed GST-E6 with in vitro synthesized p53 was associated with a disappearance of this tumor suppressor protein in a time-dependent manner (lanes 1 ± 5), while incubation with control GST did not lead to any detectable degradation (lanes 6 ± 10). When an increasing amount of GST-E6 was added, p53 was degraded in a dose-dependent manner ( Figure 2b ) with a maximal degradation of p53 at 2 mg of GST-E6. As expected, both p73a and p73b were refractory to E6-mediated degradation under the same condition ( Figure 2c , lanes 3 ± 6).
Having the in vitro degradation assay system established, we went on assessing sensitivity of the p53/p73 chimeras as shown in Figure 1b left to E6-mediated degradation. Wild type p53 was included as a positive control ( Figure 3a , lanes 1,2). The N-terminus of p53 appeared to be essential for its susceptibility to E6-mediated degradation, as replacing the p53 Nterminus (amino acids 1 ± 112) with that of p73, resulted in a p53 chimera that was no longer susceptible to degradation by E6 ( Figure 3a , lanes 3,4). The corresponding p73 chimera was still resistant to E6 (Figure 3a , lanes 5,6), suggesting that the Nterminus of p53 is necessary but not sucient for E6-mediated degradation. Previous studies have indeed reported that the p53DBD, where the E6AP/E6 complex interacts (Figure 1d ), is required for E6-directed degradation (Huibregtse et al., 1991; Schener et al., 1993) . In agreement, swapping the p53DBD also rendered the protein resistant to E6-mediated degradation (Figure 3a, lanes 7, 8) . If binding to the E6/E6-AP complex were sucient to render susceptible to degradation, introduction of the p53DBD would lead the p73 chimera being degraded. The result, however, showed that the p73 chimera that contained the p53DBD was still refractory to degradation by E6 ( Figure 3a , lanes 9,10), indicating that binding of the E6/E6-AP is not sucient to render the susceptibility. The p53 C-terminus that E6 directly bound to appeared to be dispensable for E6-targeted degrada- In vitro synthesized Flag-p53 was incubated with GST-E6 (lanes 1 ± 5) or control GST (lanes 6 ± 10) in the rabbit reticulocyte lysates at 308C. The remaining p53 was analysed at the indicated time as described in Figure 1 . (b) Flag-p53 was incubated with the indicated amount of GST-E6 protein and the disappearance of p53 was monitored by SDS ± PAGE and Western analysis. (c) In vitro translated Flag-tagged p53, p73a or p73b were incubated with GST-E6 or control GST and the products were analysed as in Figure 1 Oncogene A sequence element of p53 for viral oncoprotein-mediated degradation J Gu et al tion, since the p53 chimera with the C-terminus swapped with that of p73 was still susceptible to degradation by E6 (Figure 3a, lanes 11,12) . This observation is consistent with the reports by Li and Cono (1996a) and Marston et al. (1995) . Together, these results demonstrated that in addition to the p53DBD, the N-terminus of p53 is also necessary, but neither of them alone is sucient, to render susceptibility to E6-mediated degradation.
The N-terminus of p53 can be further divided into the transactivation domain (TAD) and the proline-rich domain (PRD). To de®ne which domain of the p53 Nterminus was essential for E6-directed degradation, we tested p53 chimeras with the TAD (residues 1 ± 45) or PRD (residues 46 ± 112) of p53 switched with the corresponding region of p73. The result was that TAD chimera remained susceptible (Figure 3b right, lanes 1,2 versus 5,6), while the PRD chimera became resistant to degradation by E6 (Figure 3b right, lanes 9,10) indicated a requirement of the PRD. To further map the essential region, the p53/p73 chimeras with more re®ned swapping at the PRD (Figure 3c left) were tested. Substituting the Figure 3 The p53(aa.92 ± 112) is required for HPV16 E6-mediated p53 degradation in vitro (a) In vitro translated products from the indicated vectors were assessed for susceptibility to degradation by E6 as described in Figure 2 . (b) p53/p73 chimeras that the Nterminus had been switched were tested for sensitivity to E6-mediated degradation. SDS ± PAGE and Western blot analysed the reaction products. (c) p53/p73 chimeras with a more re®ned swapping at the PRD (left) were assayed as in Figure 2 and the products were analysed by SDS ± PAGE and Western blot (right). (d) p53 deletion mutants as indicated (left) were assayed as in Figure 2 and the products were analysed by Western (right) as in c amino acid sequence from 46 ± 63 or 64 ± 91 of p53 with the corresponding regions of p73 did not have any apparent eect (Figure 3c right, lanes 3, 4 and 7, 8) . Switching the amino acid sequence from 92 ± 112 of p53, however, made the p53 chimera resistant to E6 mediated degradation (Figure 3c right, lanes 11,12) , indicating that the p53(aa.92 ± 112) is essential for susceptibility of p53 to degradation by E6. Interestingly, this is the same region previously identi®ed as essential for Mdm2-mediated p53 degradation.
To further strengthen the correlation between the p53(aa.92 ± 112) and susceptibility to E6-mediated degradation, a series of p53 deletion mutants at its N-terminus (Figure 3d left) were tested. The result showed that the deletion mutants lacking 1 ± 25, 26 ± 43, 44 ± 63 or 64 ± 91 of p53 were still degraded ( Figure  3d right, lanes 3 ± 10) , while only the p53(aa.92 ± 112) deletion mutant became resistant to E6-targeted degradation (Figure 3d right, lanes 11,12) . Together with the results obtained with the chimeras, we demonstrated that, in addition to the p53DBD, the p53(aa.92 ± 112) was an additional sequence element required for E6-mediated p53 degradation in vitro.
A previous study reported a lack of correlation between the in vitro and the in vivo results from a p53 mutant that was resistant to E6 in vitro but was eciently targeted for degradation in cells (Crook et al., 1996) . To test if that was the case in our study, vectors expressing the p53/p73 chimeras were cotransfected with or without HPV16 E6 into p53 de®cient MEF cells. The cells were harvested 24 h posttransfection and then analysed for protein levels by Western. As expected, wild type p53, but not wild type p73, was readily degraded by coexpression of HPV16 E6 (Figure 4a ). When the p53/p73 chimeras were cotransfected with E6, the results demonstrated that the PRD (Figure 4b , lanes 3,4 and 7,8) and DBD ( Figure 4b, lanes 9,10) , but not the TAD and Cterminus of p53 (Figure 4b , lanes 5,6 and 11,12) were required for p53 degradation in E6-expressing cells. Experiments with the more re®ned swapping at the PRD also demonstrated the p53(aa.92 ± 112) as an essential element in the PRD (Figure 4c, lanes 7,8) , consisting with the data derived from the in vitro degradation assays. An additional line of evidence to support this correlation came from the result obtained with the p53 deletion mutant that lacks the p53(aa.92 ± 112) (Figure 4d, lane 3,4) . Taken together, the results demonstrated that the p53(aa.92 ± 112) as well as the p53DBD are necessary for HPV16 E6 to target p53 for degradation both in vitro and in vivo.
In the p53/Mdm2 negative regulatory loop, Mdm2 gene is transactivated by wild type p53 and the induced Mdm2 binds to and targets p53 for degradation. Since the p53(aa.92 ± 112) was shown to be required for Mdm2-mediated p53 degradation (Gu et al., 2000) , it is possible that the endogenous Mdm2 which was induced by the expression of wild type p53 contributed to the E6-mediated p53 degradation in the cotransfection experiments. Two approaches were taken to test this possibility. First, two mutants of p53, p53(22/ 23dm) that is unable to bind to Mdm2 or p53(R273H) that is transcriptionally inactive, were examined. When coexpressed with HPV16 E6, these two p53 mutants were as sensitive as the wild type p53 (Figure 4e) . Secondly, MEFs isolated from p53 and Mdm2 double knockout mouse were used. As shown in Figure 4e (right panel), wild type and the mutant p53 were readily degraded in p53 7/7
/Mdm2
7/7 MEFs as well. Together, the results demonstrated that Mdm2 played little, if any, role in the degradation of p53 in the E6-expressing cells.
It has been reported that HPV16 E6-mediated degradation is sensitive to the conformation of p53 (Marston et al., 1995) . Although the p53/p73 chimeras had been previously shown to be transcriptionally active (Gu et al., 2000) , it is still possible that the E6-resistance of the p53/p73 chimeras is due to a subtle alteration of p53's conformation rather than lacking of the essential element, the p53(aa.92 ± 112) or the p53DBD. To address this issue, we generated a p73 chimera containing both the p53(aa.92 ± 112) and the p53DBD to determine if the combination of these two elements was sucient to render p73, which is otherwise inert, a susceptibility to E6-mediated degradation. In contrast to the p73 chimera containing either the p53(aa.92 ± 112) (Figure 4f , lanes 5,6) or the p53DBD (lanes 7,8) only, introduction of both the p53(aa.92 ± 112) and the p53DBD was indeed sucient to confer p73 susceptible to degradation in E6-expressing cells (lanes 9,10). This ®nding reinforced the notion that, in addition to the p53DBD that the E6/E6-AP binds to, the p53(aa.92 ± 112) is an additional essential element and these two domains are sucient to determine the susceptibility to E6-mediated degradation.
The p53(aa.92 ± 112) is also essential for Adenovirus E1B55k/E4 34k to target p53 for degradation Recent studies reported that E1B55k and E4 34k oncoproteins act synergistically to degrade p53 but not p73 (Querudi et al., 1997; Roth et al., 1998; Steegenga et al., 1999) . E1B55k binds to the p53 N-terminus (the amino acid 24 ± 28) and the binding is necessary but not sucient for degradation . These observations prompted us to examine whether the p53(aa.92 ± 112) was an additional element involved in this event. To test this, the p53 chimera was coexpressed with E1B55k/E4 34k in p53 7/7 MEF cells and protein levels were determined 24 h post-transfection by Western analysis. Consistent with the previous report (Querudi et al., 1997; Roth et al., 1998; Steegenga et al., 1999) , wild type p53, but not p73, was eciently targeted by E1B55k/E4 34k for degradation (Figure 5a, lanes 1,2 versus 3,4) . Strikingly, substitution of the p53(aa.92 ± 112) by the corresponding region of p73 resulted in resistance (Figure 5a , lanes 5,6), suggesting a requirement of the p53(aa.92 ± 112) for the adenoviral proteins-mediated p53 degradation. To con®rm this ®nding, the p53 deletion mutants described above were tested. In keeping with the Oncogene A sequence element of p53 for viral oncoprotein-mediated degradation J Gu et al requirement of the E1B55k binding motif (the amino acid sequence from 24 ± 28), deletion of amino acid sequence from 1 ± 25 or 26 ± 43 of p53 abrogated the viral proteins-mediated degradation (Figure 5b, lanes  1,2 and 3,4) . In contrary, removal of the fragment from amino acids residues 44 ± 63 or 64 ± 91 did not have any detectable eect (Figure 5b, lanes 5, 6 and 7, 8) . In support of the result from the chimeras (Figure 5a) , deletion of the p53(aa.92 ± 112) was associated refractory to degradation (Figure 5b, lanes 9,10) . Taken together, we demonstrated that, in addition to the Nterminal E1B55k-binding motif, the p53(aa.92 ± 112) was an additional element required for E1B55k/E4 34k to target p53 for degradation.
The necessity of this p53 sequence to the viral proteins-targeted degradation suggests that the p53(aa.92 ± 112) may also function as a determinant for the adenoviral proteins-targeted degradation. We tested this by assessing p73 chimeras who's N-terminus were replaced by the corresponding region of p53. As shown in Figure 5c , no apparent degradation was detected when the region containing only the binding domain or the p53(aa.92 ± 112) was swapped into p73 (lanes 1,2 and 3,4) . The p73 chimera containing both the domains was, however, readily degraded (lanes 11,12), indicating that the binding motif and the p53(aa.92 ± 112) are necessary and sucient to render a susceptibility to the viral oncoprotein-mediated degradation. This notion was further supported by the observation that the DBD and C-terminus of p53 were dispensable. (lanes 13,14 and 15,16) . In an eort of further con®rming this ®nding we prepared a p73 chimera with only the minimum E1B55k binding motif (residues 24 ± 28) and the p53(aa.92 ± 112) swapped. Co-expression of this chimera with E1B55k/E4 34k revealed that combination of the viral oncoprotein binding and the degradation signal was indeed sucient to render p73 susceptible to degradation Figure 4 The p53(aa.92 ± 112) is required for HPV16 E6-mediated p53 degradation in vivo. (a) Flag-tagged p53 or p73 (1 mg) expression vector was cotransfected with pSG5-empty or pSG5-E6 vector (3 mg) into p53 7/7 MEF cells. PGFP-C1 (Clontech) (0.5 mg) was included as a transfection eciency control. The transfectants were harvested 24 h post-transfection and proteins levels were analysed by Western with anti-Flag (M5, Sigma) or anti-GFP (Clontech). (b) p53/p73 chimeras with the indicated domain swapped were tested for in vivo susceptibility to E6-mediated degradation by cotransfecting with pSG5-E6. (c) p53/p73 chimeras with more re®ned swapping at the PRD were assayed for in vivo E6-mediated degradation. (d) Flag-tagged vector expressing the wild type or deletion mutant of p53 was cotransfected with or without pSG5-E6 and the protein levels were analysed by Western at 24 h after transfection. (e) Flag-tagged vector expressing the wild type, (R273H) or (22/23) mutant of p53 were cotransfected with or without pSG5-E6 into p53
MEFs (left panel) or p53
MEFs (right panel). The protein levels were determined by Western at 24 h after transfection. (f) The indicated vectors were contransfected with or without pSG5-E6 into p53
7/7
MEFs and the protein levels were analysed by Western blot (Figure 5d ). Together, we demonstrated that in addition to being necessary to the Mdm2-and HPV16 E6-mediated proteolysis of p53, the p53(aa.92 ± 112) is also required for the adenoviral oncoproteins E1B55k/E4 34k to target p53 for degradation.
Discussion
HPV16 E6 binds to and targets p53 for rapid degradation. The sequence of p53 that binds to E6 is, however, still not well de®ned. Using the p53/p73 chimeras in the GST-E6 pull-down assay, we demon- Figure 5 The p53(aa.92 ± 112) is required for adenoviral oncoprotein E1B55k/E4 34k-mediated p53 degradation. (a) Vector expressing Flag-tagged p53, p73 or the p53 chimera that the p53(aa.92 ± 112) had been substituted by the amino acid sequence from 106 ± 130 of p73 was cotransfected with E1B55K/E4 34k (1.25 mg/1.25 mg/2.0 mg=p53, or p73, or the chimera/E1B55k/E4 34k) or control empty vector into p53
MEF cells. pGFP-Cl(0.5 mg) again was included as a control. Protein levels were analysed 24 h post-transfection as in Figure 4 . (b) p53 deletion mutants as indicated were analysed for thier susceptibility to degradation in the adenoviral oncoproteins-expressing cells. (c) Vectors expressing the indicated p53/p73 chimeras were cotransfected with constructs expressing the adenoviral oncoproteins or control empty vector into p53 7/7 MEF cells. Protein levels were analysed 24 h posttransfection as described in Figure 4 . (d) Vector expressing p73 chimera that contains amino acid sequence from 24 ± 25 and 92 ± 112 of p53 at the corresponding site were cotransfected with the adenoviral proteins or control vector. Protein levels were analysed as described in Figure 4 Oncogene A sequence element of p53 for viral oncoprotein-mediated degradation J Gu et al strated the residues 364 ± 393 of p53 as a region directly binding to oncogenic E6 and the p53 DBD (residues 113 ± 290) as a second domain that binds to the E6-AP/ E6 complex.
By using the p53/p73 chimeras to examine contribution of various p53 domains to E6-mediated degradation, we obtained convincing evidence indicating a requirement of both the p53 DBD and the p53(aa.92 ± 112) in the E6-mediated degradation. In consistency with the previous reports (Li and Cono, 1996a; Marston et al., 1995) where p53 deletion mutants lacking the extreme C-terminus were shown being still degraded by E6, the C-terminal E6 binding domain was found to be dispensable for E6-mediated p53 degradation. The biological signi®cance of this Cterminal E6 binding domain is not clear, it may be involved in the E6's function other than degradation of p53 protein. In addition to the p53DBD, which has been previously shown to be required (Huibregtse et al., 1991; Schener et al., 1993) , we demonstrated the p53(aa.92 ± 112) as an additional element essential for E6-mediated degradation. Removal of this p53 sequence element by either substitution with the corresponding region of p73 or simple deletion resulted in a p53 protein that is no longer susceptible to degradation by E6. Signi®cantly, the very same p53 sequence element was previously shown to be necessary for Mdm2-mediated p53 degradation. Even though HPV16 E6 promotes p53 degradation through a mechanism distinct from that of Mdm2, both the viral oncoprotein-and Mdm2-mediated p53 degradation involve the ubqiquitin-proteosome pathway. Mdm2 has been shown to function as an E3 ubiquitin ligase that is responsible for p53 ubiquitination and subsequent degradation. Binding of Mdm2 to p73, however, did not result in degradation (Balint et al., 1999; Dobbelstein et al., 1999; Zeng et al., 1999) , suggesting the presence of an element unique to p53 that attributes this susceptibility. In keeping with this notion, we previously showed the p53(aa.92 ± 112) as an additional essential element in Mdm2-targeted degradation (Gu et al., 2000) . In the E6-mediated degradation pathway, the E6/E6-AP complex that functions as an E3 ubiquitin ligase is required to promote ubiquitination and subsequent degradation of p53 (Huibregtse et al., 1991) . The binding of the E6/ E6-AP, however, is also not sucient target p53 for degradation as we showed that the p73 chimera containing the E6/E6-AP binding domain (the p53DBD) was able to bind to the E6/E6-AP complex but remained resistant to degradation. The necessity of the p53(aa.92 ± 112) in E6-mediated degradation suggests that this p53 element can coordinate with dierent E3 ligases in targeting p53 for degradation. In E1B55k/E4 34k-targeted p53 degradation, the p53(aa.92 ± 112) was again shown to be essential to determine its stability even though it is unclear whether the adenoviral oncoprotein can function as E3 ligase.
Together, it appears that the p53(aa.92 ± 112) is an essential element that determines p53's susceptibility to degradation by three dierent oncoproteins.
Protein degradation is usually determined by a structural motif within the substrate that functions as a degradation signal and other proteins that recognize this signal. Results from our studies led us to propose the p53(aa.92 ± 112) as a degradation signal-like sequence to regulate p53 stability. This notion is supported by the observations that in the absence of this element, as in the p53 mutants where the element was either deleted or replaced, binding of the oncoproteins failed to result in degradation. p73 served as an excellent control in our study. Mdm2 binds to but is unable to degrade p73. The sequence p53(aa.92 ± 112) is not conserved in p73, which is likely attributable to this distinct sensitivity. This is supported by the ®nding that swapping the p53(aa.92 ± 112) into the corresponding region of p73 rendered the chimera susceptible to degradation by Mdm2 (Gu et al., 2000) . p73 is completely inert to E6 due to lack of interaction between p73 and the viral protein. Whereas swapping of the p53DBD rendered the p73 chimera ability to bind to the E6/E6-AP, this p73 chimera did not become susceptible to E6-mediated degradation until the p53(aa.92 ± 112) was swapped as well. Li and Cono (1996a) reported that amino acid 66 to 326 was required for E6-mediated degradation of p53, which is in general in agreement with our results. Our study, however, further de®ned the residues 112 ± 290 of p53 as the E6/E6-AP binding site and identi®ed the p53(aa.92 ± 112) as a separate essential sequence. More signi®cantly, this sequence is also required for the E1B55k/E4 34k-targeted p53 degradation. Similar to HPV16 E6 and MDM2, p73 is also resistant to the adenoviral protein. While fusion of the p53's E1B55k binding motif rendered p73 able to bind to the viral protein , no degradation of the chimera was realized until the p53(aa.92 ± 112) was introduced as well ( Figure 5 ). Collectively, our data supports a model in which the p53(aa.92 ± 112) is an essential sequence to determine p53 stability while binding of the oncoproteins directs p53 into the speci®c pathway for degradation.
How this sequence element, PLSSSVPSQKTYG-SYGFRLG, determines p53 stability is not yet known. Interestingly, Li and Cono (1996b) used a completely dierent system to demonstrate that the residues 100 ± 150 of p53 was sucient for degradation in a proteasome-dependent but ubiquitin-independent pathway, suggesting this sequence may not be necessarily involved in ubiquitination although whether the lysine residue at position 101 can be ubiquitinated remains to be determined. Even though distinct proteolysis pathways involved, Mdm2, HPV16 E6 and the E1B55k/E4 34k, the only known oncoproteins able to destabilize p53, all require the p53(aa.92 ± 112) to degrade p53, implicating its importance in the control of p53 stability. This special sequence of p53 might well be an attractive target for the development of agents to block p53 degradation and thereby reactivate p53 function in the oncoprotein-expressing tumor cells.
Material and methods
Cell culture, plasmids and transfection p53 7/7 MEF cells (P Leder Harvard Medical School) p53 7/ 7 /Mdm2 7/7 (C Maki Harvard School of Public Health) were maintained in minimal essential medium (MEM) supplemented with 10% fetal bovine serum (FBS) in 5% CO 2 at 378C. The constructs of p53/p73 chimeras and deletion mutants have been described previously (Gu et al., 2000) . Vector expressing E1B55k was obtained from Dr Y Shi (Harvard Medical School) and E4 34k was provided by Dr T Shenk (Princeton University). Cells were transfected by a calcium ± phosphate method as described (Gu et al., 2000) .
Preparation of whole-cell extracts and Western analysis. Cells were transfected in 60-mm plates with 8 mg of DNA and harvested at 24 h post-transfection. Cells were lysed in 0.1 ml of lysis buer (10 mM Tris-HCl [pH 7.5], 1 mM EDTA, 1% NP-40, 150 mM NaCl, 1 mM DTT, 0.5 mM phenylmethylsulfonyl¯uoride, protease inhibitors), and the extracts were centrifuged at 13 000 r.p.m. for 15 min to remove cell debris. Protein concentrations were determined by the Bio-Rad (Hercules, CA, USA) protein assay. After adding loading dye, samples were heated to 958C for 5 min, centrifuged for 3 min at 13 000 r.p.m., and electrophoresed through a SDS-10% polyacrylamide gel. Protein gels were transferred to nitrocellulose membranes (Schleicher and Schuell), which were probed with the indicated antibody and proteins were visualized with an enhanced chemiluminescence detection system (NEN Life Science).
In vitro degradation assay HPV16 E6-mediated in vitro degradation of p53 was performed as described (Schener et al., 1990) , with a minor modi®cation. Brie¯y, the GST fusion protein of HPV16 E6 (P Howley, Harvard Medical School), puri®ed as described (Gu et al., 2000) , was incubated with in vitro translated Flagtagged p53, p73 or the chimeras in the rabbit reticulocyte lysates (Promega) at 308C for 3 h. The reaction was stopped by adding loading dye and boiling for 5 min. The products were resolved on SDS ± PAGE, transferred and analysed by Western blot.
